Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

bayer weimar gmbh & co. kg - drospirenone, ethinylestradiol, levomefolate calcium - tablets film-coated - 3mg+30mcg+451mcg

United States - English - NLM (National Library of Medicine)

gland pharma limited - calcitriol (unii: fxc9231jvh) (calcitriol - unii:fxc9231jvh) - calcitriol injection is indicated in the management of hypocalcemia in patients undergoing chronic renal dialysis. it has been shown to significantly reduce elevated parathyroid hormone levels. reduction of pth has been shown to result in an improvement in renal osteodystrophy. calcitriol injection should not be given to patients with hypercalcemia or evidence of vitamin d toxicity. calcitriol injection is contraindicated in patients with previous hypersensitivity to calcitriol or any of its excipients.

United States - English - NLM (National Library of Medicine)

pd-rx pharmaceuticals, inc. - calcitriol (unii: fxc9231jvh) (calcitriol - unii:fxc9231jvh) - calcitriol is indicated in the management of secondary hyperparathyroidism and resultant metabolic bone disease in patients with moderate to severe chronic renal failure (ccr 15 to 55 ml/min) not yet on dialysis. in children, the creatinine clearance value must be corrected for a surface area of 1.73 square meters. a serum ipth level of ≥100 pg/ml is strongly suggestive of secondary hyperparathyroidism. calcitriol is indicated in the management of hypocalcemia and the resultant metabolic bone disease in patients undergoing chronic renal dialysis. in these patients, calcitriol administration enhances calcium absorption, reduces serum alkaline phosphatase levels, and may reduce elevated parathyroid hormone levels and the histological manifestations of osteitis fibrosa cystica and defective mineralization. calcitriol is also indicated in the management of hypocalcemia and its clinical manifestations in patients with postsurgical hypoparathyroidism, idiopathic hypoparathyroidism, and pseudohypoparathyroidism. cal

United States - English - NLM (National Library of Medicine)

sun pharmaceutical industries, inc. - calcitriol (unii: fxc9231jvh) (calcitriol - unii:fxc9231jvh) - predialysis patients calcitriol is indicated in the management of secondary hyperparathyroidism and resultant metabolic bone disease in patients with moderate to severe chronic renal failure (ccr 15 to 55 ml/min) not yet on dialysis. in children, the creatinine clearance value must be corrected for a surface area of 1.73 square meters. a serum ipth level of ≥ 100 pg/ml is strongly suggestive of secondary hyperparathyroidism. dialysis patients calcitriol is indicated in the management of hypocalcemia and the resultant metabolic bone disease in patients undergoing chronic renal dialysis. in these patients, calcitriol administration enhances calcium absorption, reduces serum alkaline phosphatase levels, and may reduce elevated parathyroid hormone levels and the histological manifestations of osteitis fibrosa cystica and defective mineralization. hypoparathyroidism patients calcitriol is also indicated in the management of hypocalcemia and its clinical manifestations in patients with postsurgic

United States - English - NLM (National Library of Medicine)

revive science, llc - histamine dihydrochloride (unii: 3poa0q644u) (histamine - unii:820484n8i3) - for the temporary relief of minor aches and pains of muscles and joints, associated with arthritis, simple back aches, strains, bruises and sprains.

United States - English - NLM (National Library of Medicine)

bryant ranch prepack - calcitriol (unii: fxc9231jvh) (calcitriol - unii:fxc9231jvh) - calcitriol is indicated in the management of secondary hyperparathyroidism and resultant metabolic bone disease in patients with moderate to severe chronic renal failure (ccr 15 to 55 ml/min) not yet on dialysis. in children, the creatinine clearance value must be corrected for a surface area of 1.73 square meters. a serum ipth level of ≥ 100 pg/ml is strongly suggestive of secondary hyperparathyroidism. calcitriol is indicated in the management of hypocalcemia and the resultant metabolic bone disease in patients undergoing chronic renal dialysis. in these patients, calcitriol administration enhances calcium absorption, reduces serum alkaline phosphatase levels, and may reduce elevated parathyroid hormone levels and the histological manifestations of osteitis fibrosa cystica and defective mineralization. calcitriol is also indicated in the management of hypocalcemia and its clinical manifestations in patients with postsurgical hypoparathyroidism, idiopathic hypoparathyroidism, and pseudohypoparathyroidism. c

United States - English - NLM (National Library of Medicine)

havasu nutrition llc - histamine dihydrochloride (unii: 3poa0q644u) (histamine - unii:820484n8i3) - for the temporary relief of minor aches and pains of muscles and joints, associated with arthritis, simple back aches, strains, bruises and sprains.

United States - English - NLM (National Library of Medicine)

cardinal health 107, llc - calcitriol (unii: fxc9231jvh) (calcitriol - unii:fxc9231jvh) - calcitriol capsule is indicated in the management of secondary hyperparathyroidism and resultant metabolic bone disease in patients with moderate to severe chronic renal failure (ccr 15 to 55 ml/min) not yet on dialysis. in children, the creatinine clearance value must be corrected for a surface area of 1.73 square meters. a serum ipth level of ≥ 100 pg/ml is strongly suggestive of secondary hyperparathyroidism. calcitriol capsule is indicated in the management of hypocalcemia and the resultant metabolic bone disease in patients undergoing chronic renal dialysis. in these patients, calcitriol administration enhances calcium absorption, reduces serum alkaline phosphatase levels, and may reduce elevated parathyroid hormone levels and the histological manifestations of osteitis fibrosa cystica and defective mineralization. calcitriol capsule is also indicated in the management of hypocalcemia and its clinical manifestations in patients with postsurgical hypoparathyroidism, idiopathic hypoparathyroidism, and pseudohypoparathyroidism. calcitriol should not be given to patients with hypercalcemia or evidence of vitamin d toxicity. use of calcitriol in patients with known hypersensitivity to calcitriol (or drugs of the same class) or any of the inactive ingredients is contraindicated.

United States - English - NLM (National Library of Medicine)

aphena pharma solutions - tennessee, llc - calcitriol (unii: fxc9231jvh) (calcitriol - unii:fxc9231jvh) - calcitriol capsules are indicated in the management of secondary hyperparathyroidism and resultant metabolic bone disease in patients with moderate to severe chronic renal failure (ccr 15 to 55 ml/min) not yet on dialysis. in children, the creatinine clearance value must be corrected for a surface area of 1.73 square meters. a serum ipth level of ≥ 100 pg/ml is strongly suggestive of secondary hyperparathyroidism. calcitriol capsules are indicated in the management of hypocalcemia and the resultant metabolic bone disease in patients undergoing chronic renal dialysis. in these patients, calcitriol capsules administration enhances calcium absorption, reduces serum alkaline phosphatase levels, and may reduce elevated parathyroid hormone levels and the histological manifestations of osteitis fibrosa cystica and defective mineralization. calcitriol capsules are also indicated in the management of hypocalcemia and its clinical manifestations in patients with postsurgical hypoparathyroidism, idiopathic hypoparathyro

United States - English - NLM (National Library of Medicine)

bryant ranch prepack - calcitriol (unii: fxc9231jvh) (calcitriol - unii:fxc9231jvh) - calcitriol capsules are indicated in the management of secondary hyperparathyroidism and resultant metabolic bone disease in patients with moderate to severe chronic renal failure (ccr 15 to 55 ml/min) not yet on dialysis. in children, the creatinine clearance value must be corrected for a surface area of 1.73 square meters. a serum ipth level of ≥ 100 pg/ml is strongly suggestive of secondary hyperparathyroidism. calcitriol capsules are indicated in the management of hypocalcemia and the resultant metabolic bone disease in patients undergoing chronic renal dialysis. in these patients, calcitriol capsules administration enhances calcium absorption, reduces serum alkaline phosphatase levels, and may reduce elevated parathyroid hormone levels and the histological manifestations of osteitis fibrosa cystica and defective mineralization. calcitriol capsules are also indicated in the management of hypocalcemia and its clinical manifestations in patients with postsurgical hypoparathyroidism, idiopathic hypoparathyro